The Shingrix vaccine from GSK PLC - robust shingles protection for older adults

The Shingrix vaccine offers a two-dose regimen with over 90% efficacy against shingles in adults over 50. This bestseller drives the price of GSK PLC shares (ISIN GB0009252882).

Reviewed: ad hoc news B2B & Pro desk. Edited and checked on 2026-06-27, 19:02. Details in the imprint.

The Shingrix vaccine sits in a cool, stainless-steel tray in a GP practice fridge, a small carton promising to spare older adults the raw nerve pain of shingles. The nurse shakes the vial gently, checks the name twice, and tells the patient this is GSK's current standard for shingles prevention.

What Shingrix is designed to do

Shingrix from GSK PLC is a recombinant, non-live shingles vaccine aimed primarily at adults aged 50 and older. It uses a varicella-zoster virus glycoprotein combined with an adjuvant system to stimulate a strong immune response.Official GSK product information on Shingrix

The vaccine is given in a two-dose schedule, typically spaced two to six months apart, which many clinicians see as a practical compromise between convenience and durable protection.Clinical guidance from CDC on Shingrix use

Efficacy and real-world impact

According to pivotal clinical trials, Shingrix demonstrated more than 90% efficacy in preventing shingles in adults aged 50 and older, and around 85% efficacy in those aged 70 and above.New England Journal of Medicine data on Shingrix efficacy

For many patients, that translates into fewer weeks of burning, band-like rash and a lower risk of lingering postherpetic neuralgia, the quiet but debilitating nerve pain that can follow a shingles episode.

How it is administered in practice

In many markets, Shingrix is supplied as a two-part kit, with a lyophilised antigen component and a liquid adjuvant that must be mixed immediately before injection. That mixing step gives the nurse a brief moment to explain possible side effects and benefits.

The injection is given intramuscularly, typically in the upper arm, and some recipients describe a firm, sore feeling at the site for one or two days. For clinicians like Dr. Kate Smith, a London-based GP, that transient discomfort is acceptable compared to the severe pain of shingles later in life.

Side effects and tolerability profile

Commonly reported adverse reactions include pain at the injection site, redness, swelling, fatigue, muscle pain, headache, shivering and fever. Many of these reactions resolve within a few days and are consistent with a strong immune stimulation.

Because Shingrix is a non-live vaccine, it is considered suitable for some immunocompromised patients, which was a deliberate design choice highlighted repeatedly by GSK's vaccine leadership team under CEO Emma Walmsley.

Positioning in GSK's vaccine portfolio

Shingrix sits alongside GSK's broader adult vaccine portfolio, which includes products for influenza, pneumococcal disease and other infections. Its strong commercial performance has turned it into a strategic pillar in GSK's vaccines business.

For health systems, the vaccine is often part of a wider push to keep older adults active and independent, reducing hospital stays and long-term complications linked to preventable infections.

Market availability and pricing

Shingrix is approved and marketed in major regions including the US, Europe and several Asian markets, often under national immunization program guidance. In the US, the wholesale acquisition cost per dose is usually quoted in the high-hundreds of dollars for the full two-dose course.

In Europe, pricing varies by country and reimbursement model, with some national health services covering the vaccine for defined age groups, while others rely on private payment or supplementary insurance models.

Where GSK shares stand

Shingrix is one of the products investors regularly track when they assess GSK PLC's vaccine performance and earnings guidance. The GSK PLC share price (ISIN GB0009252882) trades on the London Stock Exchange, with recent quotes around 1,970 pence according to UK brokers.

Key facts on Shingrix

• Product: Shingrix vaccine
• Manufacturer: GSK plc
• Category: B2B/Pro line - prescription vaccine for healthcare professionals
• Launch: First approved in the US in 2017, with subsequent launches in Europe and other markets
• RRP / Price: Typically a two-dose course, with US wholesale acquisition cost quoted in the high-hundreds of dollars for both doses; country-specific pricing in Europe
• Availability: Distributed via healthcare providers, hospitals and vaccination clinics in markets where it is approved
• Target group: Adults aged 50 years and older, and selected high-risk individuals as determined by clinical guidelines
• Highlight / USP: High efficacy against shingles in older adults and a non-live, adjuvanted design suitable for certain immunocompromised patients

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.